UNASSIGNED: In this randomized controlled clinical trial, patients with cutaneous leishmaniasis were assigned to experimental (n = 18) and control (n = 18) groups. Both groups received intralesional meglumine antimoniate (Glucantime®). The experimental group also received 5% Brazambel extract ointment once a day. The interventions continued until the complete healing of the lesions (reepithelialization) for a maximum of 8 weeks. The clinical response, defined as complete response (reepithelialization >75%), partial response (reepithelialization 50%-75%), or treatment failure (reepithelialization <50%), was compared between the groups.
UNASSIGNED: The percentage of reepithelialization in the experimental group (4th week: 64.44 ± 25.13; 8th week: 83.85 ± 11.54) was higher than the control group (4th week: 53.97 ± 25.88; 8th week: 76.27 ± 21.67); however, the differences were not statistically significant (P = 0.252 and 0.494, respectively). Moreover, there was no significant difference between the experimental and control groups regarding the rate of complete healing (88.9% vs. 72.2%, respectively).
UNASSIGNED: The use of P. abrotanoides extract 5% topical formulation does not affect the healing of cutaneous leishmaniasis.
■在这项随机对照临床试验中,皮肤利什曼病患者被分为实验组(n=18)和对照组(n=18).两组均接受病灶内的锑酸葡甲胺(Glucantime®)。实验组还每天一次接受5%Brazambel提取物软膏。干预持续至病变完全愈合(再上皮化)最长8周。临床反应,定义为完全反应(上皮再生>75%),部分反应(上皮再生50%-75%),或治疗失败(上皮再生<50%),进行组间比较。
■实验组(第4周:64.44±25.13;第8周:83.85±11.54)的再上皮形成百分比高于对照组(第4周:53.97±25.88;第8周:76.27±21.67);但是,差异无统计学意义(分别为P=0.252和0.494).此外,在完全愈合率方面,实验组和对照组之间没有显着差异(88.9%vs.72.2%,分别)。
■使用巴豆提取物5%局部制剂不影响皮肤利什曼病的愈合。